| Literature DB >> 35163027 |
Stefano Amatori1, Mirco Fanelli1.
Abstract
Cancer cells accumulate epigenomic aberrations that contribute to cancer initiation and progression by altering both the genomic stability and the expression of genes. The awareness of such alterations could improve our understanding of cancer dynamics and the identification of new therapeutic strategies and biomarkers to refine tumor classification and treatment. Formalin fixation and paraffin embedding (FFPE) is the gold standard to preserve both tissue integrity and organization, and, in the last decades, a huge number of biological samples have been archived all over the world following this procedure. Recently, new chromatin immunoprecipitation (ChIP) techniques have been developed to allow the analysis of histone post-translational modifications (PTMs) and transcription factor (TF) distribution in FFPE tissues. The application of ChIP to genome-wide chromatin studies using real archival samples represents an unprecedented opportunity to conduct retrospective clinical studies thanks to the possibility of accessing large cohorts of samples and their associated diagnostic records. However, although recent attempts to standardize have been made, fixation and storage conditions of clinical specimens are still extremely variable and can affect the success of chromatin studies. The procedures introduced in the last few years dealt with this problem proponing successful strategies to obtain high-resolution ChIP profiles from FFPE archival samples. In this review, we compare the different FFPE-ChIP techniques, highlighting their strengths, limitations, common features, and peculiarities, as well as pitfalls and caveats related to ChIP studies in FFPE samples, in order to facilitate their application.Entities:
Keywords: FFPE tissues; archival samples; cancer epigenetics; chromatin; chromatin immunoprecipitation (ChIP)
Mesh:
Year: 2022 PMID: 35163027 PMCID: PMC8834906 DOI: 10.3390/ijms23031103
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Figure 1Timeline of the FFPE-ChIP procedures and kits introduced over time. Procedures are in rectangles while kits are in ovals. Specific colors are used for each research group and company.
Overview of the FFPE-ChIP procedures and kits analyzed in this review.
| PAT-ChIP | FiT-seq | EPAT-ChIP | Chrom-EX PE | FiTAc-seq | RCRA ChIP-seq | FACT-seq | ChIP-IT FFPE Chromatin Preparation II | truChIP FFPE | |
|---|---|---|---|---|---|---|---|---|---|
|
| Procedure | Procedure | Procedure | Procedure | Procedure | Procedure | Procedure | Commercial kit | Commercial kit |
|
| 11/2010 | 04/2016 | 11/2018 | 03/2019 | 07/2019 | 04/2021 | 09/2021 | 2018 (previous version: 2014) | 12/2018 |
|
| 4 days | N.A. | 3 days | 4 days | 4 days | 2–3 days | 5 days | 1 day (only chromatin preparation) ** | 1 day (only chromatin preparation) ** |
|
| 10 | 10 | 10 | 20 | 10 | 8 | 10–20 | 5–10 | 10 |
|
| 4 | 10 | 2–4 | 2 | 2–4 | 1–2 | 1 | up to 5 | 2 |
|
| [ | [ | [ | [ | [ | [ | [ |
N.A.: indicates that the information is not available in published manuscripts. * For all procedures, a further day may be required to evaluate chromatin abundance and fragmentation prior to immunoselection. ** The reported commercial kits include only chromatin extraction, while other kits of the same suppliers are indicated for chromatin immunoselection.
Figure 2Schematic overview of the main steps shared by the different procedures described in this review. FFPE tissue sections can be collected from the block as a whole or dissected (macro- or micro-) to enrich the starting material of specific tissue components. The sections are deparaffinized and rehydrated prior to be subjected to limited reversal of crosslinking by heat and chromatin extraction and shearing by focused ultrasonication or canonical probe sonication. Then, chromatin should be checked prior to proceed with immunoselection: an aliquot of chromatin is taken and decrosslinked, and the DNA is purified, fluorimetrically quantified, and separated by electrophoresis to evaluate the size of fragments. Chromatin is then immunoselected using antibodies directed against the protein or histone modification of interest. After capture of chromatin–antibody complexes and their washing to remove the nonspecific chromatin binding, selected chromatin is decrosslinked and purified using spin-column strategies. Finally, a preliminary evaluation of the specificity of the immunoselection by real-time qPCR should be performed prior to library preparation and NGS sequencing.
Summary of the procedural steps used by the different FFPE-ChIP techniques and kits for tissue processing before chromatin isolation.
| PAT-ChIP | FiT-seq | EPAT-ChIP | Chrom-EX PE | FiTAc-seq | RCRA ChIP-seq | ChIP-IT FFPE Chromatin Preparation II | truChIP FFPE | |
|---|---|---|---|---|---|---|---|---|
|
| Histolemon, 5 times for 10 min | Xylene, 3 times | Histolemon, 5 times for 10 min | Xylene | Xylene | Xylene, 3 times | Xylene, 3 times | None |
|
| 100, 95, 70, 50, 20, 0 | 95, 80, 70, 50, 20, 0 | 100, 95, 70, 50, 20, 0 | 95, 70, 50, 20 | 100, 70, 0 | 100, 95, 80, 70, 50, 20, 0 | 100, 70, 50, 20, 0 | None |
|
| 30 min at RT with 0.5% Tween-20 and 10 µg/mL RNase A | 1 h at 40 °C with 0.1% SDS | 30 min at RT with 0.5% Tween-20 and 10 µg/mL RNase A | None | None | None | None | None |
|
| Probe sonicator, 3 × 30 s at 40% amplitude | None | Probe sonicator, 3 × 30 s at 40% amplitude | None | None | None | None | None |
Conditions are reported only if published or described in kit datasheets. Buffer composition: in the absence of other relevant features, only the concentrations of detergents and salts are reported.
Summary of the procedural steps used by the different FFPE-ChIP techniques and kits for chromatin extraction.
| PAT-ChIP | FiT-seq | EPAT-ChIP | Chrom-EX PE | FiTAc-seq | RCRA ChIP-seq | ChIP-IT FFPE Chromatin Preparation II | truChIP FFPE | |
|---|---|---|---|---|---|---|---|---|
|
| 1 min at 37 °C with 0.1 U MNase/µg of chromatin | None | None | None | None | None | None | None |
|
| None | 40 ng/µL for 5–10 min | None | None | None | None | None | 80 ng/μL for 10 min at 40 °C |
|
| None | None | 1 h at 80 °C with 0.05% Tween-20 | 16 h at 65 °C with 0.5% Triton-X 100 and 0.1% sodium deoxycholate | 16 h at 65 °C with 1% SDS | 60 min at 65 °C followed by 30 min at 90 °C in 0.1% SDS | 1 h at 50 °C in “ChIP buffer” | None |
|
| None | None | None | 10 min in ice with 0.5% IGEPAL | None | None | None | None |
|
| None | None | None | None | None | None | None | Covaris M220, 5 min at 20 °C (duty factor 20%, peak incident 75 W, 200 cycles per burst) |
|
| Probe sonicator, 3 × 30 s at 85% amplitude in 0.1% SDS | Covaris E210, 40 min in 0.1% SDS (duty factor 20%, intensity 8, 200 cycles per burst) | Probe sonicator, 3 × 30 s at 40% amplitude in 0.1% SDS | Bioruptor Twin (UCD-400), 3 × (30 × 30 s) in 1% Triton X-100, 0.1% sodium deoxycholate, 0.05% SDS | Covaris E220 5 min in 1% SDS (duty factor 5%, peak incident 105 W, 200 cycles per burst) | Bioruptor II, 60 × 30 s in 1% Triton-X 100, 0.5% IGEPAL (BM Equipment) | Probe sonicator, 40 × 30 s at 42% amplitude in “ChIP buffer” | Covaris M220, 10–30 min at 7 °C (duty factor 15%, peak incident 75 W, 200 cycles per burst) after the addition of “shearing buffer” |
Conditions are reported only if published or described in kit datasheets. Buffer composition: in the absence of other relevant features, only the concentrations of detergents and salts are reported.
Summary of the procedural steps used by the different FFPE-ChIP procedures for chromatin immunoselection and DNA purification.
| PAT-ChIP | FiT-seq | EPAT-ChIP | Chrom-EX PE | FiTAc-seq | RCRA ChIP-seq | |
|---|---|---|---|---|---|---|
|
| 0.5–4 µg | N.A. | 0.4–2 µg | N.A. | >0.4 µg (in the presence of 20 μg recombinant H2B and 1 μg reference total RNA) | 0.4–2 µg |
|
| 16 h at +4 °C in 0.02% SDS, 50 mM NaCl | Protein G Agarose Columns (Active Motif) | 16 h at +4 °C in 0.02% SDS, 50 mM NaCl | 16 h in 1% Triton X-100, 0.1% sodium deoxycholate, 0.05% SDS | 16 h at 4 °C in 0.1% SDS, 1% Triton X-100, 150 mM NaCl | In an ultrasonic water bath for 40 min in 150 mM NaCl, 1% Triton X-100, 0.5% IGEPAL |
|
| Protein G-Sepharose beads | Protein G-Sepharose beads | Protein G magnetic beads | Protein A and protein G magnetic beads | Protein G magnetic beads | |
|
| 3 times with high volumes (10 mL) of 1% Triton X-100 and increasing NaCl concentrations (50, 100, and 150 mM) | 3 times with high volumes (10 mL) of 1% Triton-X 100 and increasing NaCl concentrations (50, 100, and 150 mM) | 4 times with: (i) 100 mM NaCl, 1% Triton X-100, 0.1% sodium deoxycholate; (ii) 500 mM NaCl, 1% Triton X-100, 0.1% sodium deoxycholate; (iii) 0.25 M LiCl2, 0.5% NP-40, 0.5% sodium deoxycholate; (iv) TE buffer | 6 times with 0.7% sodium deoxycholate, 1% NP40, 0.5 M LiCl | 4 times with: (i) 150 mM NaCl, 1% Triton X-100, 0.5% IGEPAL (2 times); (ii) 300 mM NaCl, 1% Triton X-100, 0.1% SDS, 0.1% Na-deoxycholate; (iii) 250 mM LiCl, 1% Triton X-100, 0.5% Na-deoxycholate | |
|
| With 1% SDS | With 1% SDS | N.A. | With 1% SDS | With 1% SDS | |
|
| 16 h at 65 °C in the presence of 0.2 M NaCl | N.A. | 16 h at 65 °C in the presence of 0.2 M NaCl | 16 h at 65 °C | 6–16 h at 65 °C | 16 h at 65 °C in the presence of 0.2 M NaCl |
|
| Phenol–chloroform | N.A. | QIAquick PCR Purification Kit (Qiagen, Hilden, Germany) | MinElute PCR purification kit (Qiagen, Hilden, Germany) | QIAquick PCR Purification Kit (Qiagen, Hilden, Germany) | QIAquick PCR Purification Kit (Qiagen, Hilden, Germany) or Agencourt AMPure XP (Beckman Coulter, Brea, CA, USA) |
|
| None | None | None | None | None | PreCR Repair Mix (New England Biolabs, Beverly, MA, USA) |
N.A. indicates that the information is not available in published manuscripts. Conditions are reported only if published or described in kit datasheets. Buffer composition: in the absence of other relevant features, only the concentrations of detergents and salts are reported.
Figure 3Identification of H3K4me3 control regions for the evaluation of the specificity of the immunoselection by real-time qPCR. Regions known to be enriched or not enriched can be used for antibody titration and to evaluate the specificity of the immunoselected DNA prior to library preparation and sequencing. Snapshots of mouse H3K4me3-enriched (ACTB) and not enriched (COL2A1) gene promoters are shown as example. ChIP-Seq data are from the ENCODE project and were taken from UCSC Genome Browser (http://genome.ucsc.edu (accessed on 7 November 2021)). The sequences we used to amplify as a control of specificity of H3K4me3 experiments on mouse tissues are indicated by the light-red vertical bars.